Levodopa/carbidopa/entacapone (Stalevo)HAUSER, Robert A.Neurology. 2004, Vol 62, Num 1, pp S64-S71, issn 0028-3878, SUP1Article

Trichophagia Affects Response to Duodenal Levodopa/Carbidopa Gel AdministrationMÜLLER, Thomas; HAAS, Thomas; LÜTGE, Sven et al.Movement disorders. 2012, Vol 27, Num 4, pp 588-590, issn 0885-3185, 3 p.Article

Severe Gastrointestinal Complications in Patients With Levodopa/Carbidopa Intestinal Gel InfusionKLOSTERMANN, Fabian; JUGEL, Constanze; BÖMELBURG, Miriam et al.Movement disorders. 2012, Vol 27, Num 13, pp 1704-1705, issn 0885-3185, 2 p.Article

The hydrosoluble fiber Plantago ovata husk improves levodopa (with carbidopa) bioavailability after repeated administrationDIEZ, M. Jose; GARCIA, Juan J; PRIETO, Carlos et al.Journal of the neurological sciences. 2008, Vol 271, Num 1-2, pp 15-20, issn 0022-510X, 6 p.Article

Carbidopa/Levodopa Pharmacy Errors in Parkinson's DiseaseKHADEM, Nasim R; NIRENBERG, Melissa J.Movement disorders. 2010, Vol 25, Num 16, pp 2867-2871, issn 0885-3185, 5 p.Article

Simultaneous determination of levodopa and carbidopa by synchronous fluorescence spectrometry using double scansWOOK HYUN KIM; MOHAMMAD MAINUL KARIM; SANG HAK LEE et al.Analytica chimica acta. 2008, Vol 619, Num 1, pp 2-7, issn 0003-2670, 6 p.Conference Paper

Oxidation of carbidopa by tyrosinase and its effect on murine melanomaGASOWSKA-BAJGER, Beata; FRACKOWIAK-WOJTASEK, Bozena; KOJ, Sabina et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 13, pp 3507-3510, issn 0960-894X, 4 p.Article

Evolution of the Bioavailability and other Pharmacokinetic Parameters of Levodopa (with Carbidopa) in RabbitsFERNDNDEZ, N; PRIETO, C; SIERRA, M et al.Methods and findings in experimental and clinical pharmacology. 2008, Vol 30, Num 6, pp 451-457, issn 0379-0355, 7 p.Article

Simultaneous kinetic determination of levodopa and carbidopa by H-point standard addition methodSAFAVI, Afsaneh; TOHIDI, Maryam.Journal of pharmaceutical and biomedical analysis. 2007, Vol 44, Num 1, pp 313-318, issn 0731-7085, 6 p.Article

Carbidopa dosage modifies L-DOPA induced side effects and blood levels of L-DOPA and other aminoacids in advanced parkinsonismPAREJA, F. B; MARTINEZ-MARTIN, P; MURADAS, V et al.Acta neurologica scandinavica. 1985, Vol 72, Num 5, pp 506-511, issn 0001-6314Article

Carbidopa/levodopa-responsive myoclonusFITZGERALD, David B; DRAGO, Valeria; SUTHERLAND, Dean et al.Movement disorders. 2007, Vol 22, Num 3, pp 392-395, issn 0885-3185, 4 p.Article

Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patientsEARLEY, C. J; ALLEN, R. P.Sleep (New York, NY). 1996, Vol 19, Num 10, pp 801-810, issn 0161-8105Article

Use of integral and differential methods for the determination of L-dopa in pure form and pharmaceutical preparationsHELALEH, M. I. H; RAHMAN, N; JAMHOUR, R. M. A. Q et al.Journal of pharmaceutical and biomedical analysis. 1997, Vol 16, Num 2, pp 269-274, issn 0731-7085Article

The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulationJORGA, K; FOTTELER, B; SEDEK, G et al.Journal of neurology. 1998, Vol 245, Num 4, pp 223-230, issn 0340-5354Article

Development and Application of a High-Performance Liquid Chromatographic Method for the Determination of In Vitro Drug Release of Levodopa, Carbidopa, and Entacapone from a Tablet FormulationDOSHI, Ashish S; UPADHYAY, Kalpesh J; MEHTA, Tushar N et al.Journal of AOAC International. 2009, Vol 92, Num 2, pp 394-403, issn 1060-3271, 10 p.Article

Response of Motor Complications in Cockayne Syndrome to Carbidopa-LevodopaNEILAN, Edward G; DELGADO, Mauricio R; DONOVAN, Melissa A et al.Archives of neurology (Chicago). 2008, Vol 65, Num 8, pp 1117-1121, issn 0003-9942, 5 p.Article

Entacapone in restless legs syndromeSHARIF, Ashfaq A.Movement disorders. 2002, Vol 17, Num 2, issn 0885-3185, p. 421Article

Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatmentBROWN, W. D; OAKES, T. R; DEJESUS, O. T et al.The Journal of nuclear medicine (1978). 1998, Vol 39, Num 11, pp 1884-1891, issn 0161-5505Article

Hyperdopaminergic crises in familial dysautonomia: A randomized trial of carbidopaNORCLIFFE-KAUFMANN, Lucy; MARTINEZ, Jose; AXELROD, Felicia et al.Neurology. 2013, Vol 80, Num 17, pp 1611-1617, issn 0028-3878, 7 p.Article

Long-term follow-up of L-dopa treatment in children with amblyopiaLEGUIRE, Lawrence E; KOMAROMY, Kelly L; NAIRUS, Theresa M et al.Journal of pediatric ophthalmology and strabismus. 2002, Vol 39, Num 6, pp 326-330, issn 0191-3913, 5 p.Article

Carbidopa/levodopa for smoking cessation: a pilot study with negative resultsHURT, R. D; AHLSKOG, J. E; CROGHAN, G. A et al.Nicotine & tobacco research. 2000, Vol 2, Num 1, pp 71-78, issn 1462-2203Article

Effects of carbidopa and of intravenous saline infusion into normal and hypertensive subjects on urinary free and conjugated dopamineSTOKES, G. S; MONAGHAN, J. C; PILLAI, D. N et al.Journal of hypertension. 1997, Vol 15, Num 7, pp 761-768, issn 0263-6352Article

Deceleration of light-induced changes of selected pharmacons by means of light screening filmsTURY, G; SZABO, G. T; VABRIK, R et al.Journal of photochemistry and photobiology. A, Chemistry. 1997, Vol 111, Num 1-3, pp 171-179, issn 1010-6030Article

Initiating Levodopa/Carbidopa Therapy With and Without Entacapone in Early Parkinson Disease: The STRIDE-PD StudySTOCCHI, Fabrizio; RASCOL, Olivier; KIEBURTZ, Karl et al.Annals of neurology. 2010, Vol 68, Num 1, pp 18-27, issn 0364-5134, 10 p.Article

Blood-brain barrier and neuronal membrane transport of 6-[¹⁸F]fluoro-L-DOPAYEE, Randa E; CHENG, David W; HUANG, Sung-Cheng et al.Biochemical pharmacology. 2001, Vol 62, Num 10, pp 1409-1415, issn 0006-2952Article